Massachusetts - based DNA Inc has raised $ 144 m in an initial public offering to help fund its first clinical trials . The company claims to have a superior version of existing gene - editing methods , including c - Cas9 , by making use of a natural biological process called homologous recombination by which body cells repair DNA damage . Homology is also developing gene therapies that use disease - associated viruses ( gene therapy delivery tools ) developed in - house . The company 's first clinical trials will target the genetic disorder phenylketonuria , initially in adults Homology had planned to sell 7.6 million shares at $14 to $16 each. and then later this year in children .
Massachusetts - based DNA Inc has raised $ 144 m in an initial public offering to help fund its first clinical trials . The company claims to have a superior version of existing gene - editing methods , including c - Cas9 , by making use of a natural biological process called homologous recombination by which body cells repair DNA damage . Homology is also developing gene therapies that use disease - associated viruses ( gene therapy delivery tools ) developed in - house . The company 's first clinical trials will target the genetic disorder phenylketonuria , initially in adults and then later this year in children .